|
Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass
RECRUITINGN/ASponsored by Cairo University
Actively Recruiting
PhaseN/A
SponsorCairo University
Started2025-12-01
Est. completion2026-06
Eligibility
Age21 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07248202
Summary
This study compares ketamine/fentanyl versus ketamine/lidocaine in term of their impact on cerebral perfusion during CABG. No prior data address these effects, and the goal is to identify the induction regimen that better preserves cerebral oxygenation.
Eligibility
Age: 21 Years+Healthy volunteers accepted
Inclusion Criteria: * patients with coronary artery disease * with moderate to severe left ventricular dysfunction (ejection fraction \< 40%), * scheduled for elective CABG surgery Exclusion Criteria: * associated chronic stroke, TIA , carotid occlusive disease( due to abnormal vasomotor activity), patients with known neurological impairment (cerebral infarction , dementia ), significant carotid artery stenosis , * valvular heart disease, * persistent arrhythmias, * congestive cardiac failure, * on mechanical ventilation, * intra-aortic balloon pump, * emergency surgery, * and those with known allergy to any of the study's drugs, * severe systemic non-cardiac disease and * patients with baseline NIRS reading \< 60% * Patients with dementia or visual or auditory impairment
Conditions8
Coronary Artery Disease (CAD)Coronary Bypass Graft SurgeryFentanylHeart DiseaseInduction AnesthesiaKetamineLeft Ventricular (LV) Systolic DysfunctionLidocaine
Interventions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorCairo University
Started2025-12-01
Est. completion2026-06
Eligibility
Age21 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07248202